MG
LNAI

Michael Gelband’s Lunai Bioworks LNAI Stock Holding History

Michael Gelband’s Portfolio LNAI Stock Details LNAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-151
Closed -$3K – 1936
2025
Q2 		$3K Buy
+151
New +$4.22K ﹤0.01% 1405
2024
Q2 		– Sell
-735
Closed -$156K – 1904
2024
Q1 		$156K Buy
735
+423
+136% +$114K ﹤0.01% 1384
2023
Q4 		$79K Buy
+312
New +$85.5K ﹤0.01% 1368
2022
Q2 		– Sell
-639
Closed -$422K – 2359
2022
Q1 		$422K Sell
639
-26
-4% -$13.8K 0.01% 1630
2021
Q4 		$388K Buy
+665
New +$483K ﹤0.01% 1545
2019
Q2 		– Sell
-409
Closed -$227K – 1291
2019
Q1 		$227K Buy
+409
New +$239K 0.02% 529

Other funds holding LNAI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Michael Gelband's LNAI Position: Q3 2025 in Review

Michael Gelband sold out of Lunai Bioworks (LNAI) in Q3 2025, closing a stake of 151 shares — an estimated $3K sold.

Michael Gelband first reported a position in LNAI in Q1 2019 and held it in 6 quarters. The position peaked at $422K in Q1 2022. 20 funds tracked by Wall St. Rank hold LNAI as of Q3 2025.

  • Michael Gelband reported no remaining Lunai Bioworks position as of Q3 2025 after selling out during the quarter.
  • Michael Gelband sold 151 Lunai Bioworks shares in Q3 2025, an estimated $3K.
  • Michael Gelband first reported a position in Lunai Bioworks in Q1 2019 and held it in 6 quarters.
  • Michael Gelband's Lunai Bioworks position peaked at $422K in Q1 2022.
  • 20 funds tracked by Wall St. Rank held Lunai Bioworks as of Q3 2025.

Based on ExodusPoint Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.